Literature DB >> 33572801

ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.

Eleanor Williams1, Elise Riesebos1,2, Georgina Kerr1, Alex N Bullock1.   

Abstract

The immunophilin FKBP12 is a known inhibitor of type I BMP and TGF-β receptors that competes for binding with their substrate SMADs. FKBP12 and the close paralog FKBP12.6 additionally assemble with ryanodine receptors to control Ca2+ release. Binding of FKBP12.6 to BMP/TGF-β receptors has yet to be investigated, but appears plausible given its high sequence similarity to FKBP12. Here, we found that FKBP12.6 can assemble with BMP and TGF-β-family type I receptors, but not with type II receptors. Cellular immunoprecipitation confirmed similar binding of FKBP12 and FKBP12.6 to the BMP receptor ALK2 (ACVR1), a known target of mutations in the congenital syndrome fibrodysplasia ossificans progressiva (FOP), as well as the pediatric brain tumor diffuse intrinsic pontine glioma (DIPG). SEC-MALS analyses using purified proteins indicated a direct 1:1 interaction between FKBP12.6 and the receptor's cytoplasmic domains. The 2.17 Å structure of this ALK2-FKBP12.6 complex bound to the inhibitor dorsomorphin showed FKBP12.6 binding to the GS domain of ALK2 in a manner equivalent to the FKBP12 complex, with ALK2 residues Phe198 and Leu199 extending into the FK506-binding pocket of FKBP12.6. These findings suggest a level of redundancy in FKBP-family regulation of BMP and TGF-β signaling.

Entities:  

Keywords:  ACVR1; ALK2; BMP; FKBP12; FKBP12.6; fibrodysplasia ossificans progressiva; kinase

Year:  2021        PMID: 33572801      PMCID: PMC7911104          DOI: 10.3390/biomedicines9020129

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  37 in total

1.  The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors.

Authors:  T Wang; B Y Li; P D Danielson; P C Shah; S Rockwell; R J Lechleider; J Martin; T Manganaro; P K Donahoe
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 2.  FK506-Binding Proteins and Their Diverse Functions.

Authors:  Mingming Tong; Yu Jiang
Journal:  Curr Mol Pharmacol       Date:  2015       Impact factor: 3.339

3.  Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes.

Authors:  Cindy R Sinars; Joyce Cheung-Flynn; Ronald A Rimerman; Jonathan G Scammell; David F Smith; Jon Clardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

4.  Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.

Authors:  Paul B Yu; Charles C Hong; Chetana Sachidanandan; Jodie L Babitt; Donna Y Deng; Stefan A Hoyng; Herbert Y Lin; Kenneth D Bloch; Randall T Peterson
Journal:  Nat Chem Biol       Date:  2007-11-18       Impact factor: 15.040

Review 5.  TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

Authors:  Bernhard Schmierer; Caroline S Hill
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

6.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

Review 7.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

8.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

Review 9.  FKBP Ligands-Where We Are and Where to Go?

Authors:  Jürgen M Kolos; Andreas M Voll; Michael Bauder; Felix Hausch
Journal:  Front Pharmacol       Date:  2018-12-05       Impact factor: 5.810

10.  Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.

Authors:  Chen Xie; Wenjuan Jiang; Jerome J Lacroix; Yun Luo; Jijun Hao
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

View more
  1 in total

1.  Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches".

Authors:  Roberto Ravazzolo
Journal:  Biomedicines       Date:  2022-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.